Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia

Han Na Suh; Sohee Jun; Ah-Young Oh; Mrinal Srivastava; Sunhye Lee; Cullen M Taniguchi; Songlin Zhang; Won Sup Lee; Junjie Chen; Bum-Joon Park; Jae-Il Park

doi:10.1038/srep38273

Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia

Sci Rep. 2016 Dec 6:6:38273. doi: 10.1038/srep38273.

Authors

Han Na Suh¹, Sohee Jun¹, Ah-Young Oh², Mrinal Srivastava¹, Sunhye Lee¹, Cullen M Taniguchi¹, Songlin Zhang³, Won Sup Lee⁴, Junjie Chen¹, Bum-Joon Park², Jae-Il Park^{1

5

6}

Affiliations

¹ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
² Department of Molecular Biology, Pusan National University, Busan, Republic of Korea.
³ Department of Pathology, The University of Texas Medical School, Houston, TX, 77030, USA.
⁴ Department of Internal Medicine, Gyeong-Sang National University Hospital, Jinju, Republic of Korea.
⁵ Graduate School of Biomedical Sciences at Houston, Houston, TX, 77030, USA.
⁶ Program in Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Abstract

Pancreatic cancer is one of the most aggressive cancers and has an extremely poor prognosis. Despite recent progress in both basic and clinical research, most pancreatic cancers are detected at an incurable stage owing to the absence of disease-specific symptoms. Thus, developing novel approaches for detecting pancreatic cancer at an early stage is imperative. Our in silico and immunohistochemical analyses showed that KIAA1199 is specifically expressed in human pancreatic cancer cells and pancreatic intraepithelial neoplasia, the early lesion of pancreatic cancer, in a genetically engineered mouse model and in human patient samples. We also detected secreted KIAA1199 protein in blood samples obtained from pancreatic cancer mouse models, but not in normal mice. Furthermore, we found that assessing KIAA1199 autoantibody increased the sensitivity of detecting pancreatic cancer. These results indicate the potential benefits of using KIAA1199 as a biomarker for early-stage pancreatic cancer.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Acute Disease
Animals
Autoantibodies / biosynthesis
Autoantibodies / blood*
Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics*
Carcinoma, Pancreatic Ductal / diagnosis
Carcinoma, Pancreatic Ductal / genetics*
Carcinoma, Pancreatic Ductal / immunology
Carcinoma, Pancreatic Ductal / pathology
Cell Line, Tumor
Ceruletide
Databases, Genetic
Disease Models, Animal
Early Diagnosis
Gene Expression Profiling
Gene Expression Regulation, Neoplastic*
Humans
Hyaluronoglucosaminidase
Male
Mice
Mice, Inbred C57BL
Pancreatic Neoplasms / diagnosis
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / immunology
Pancreatic Neoplasms / pathology
Pancreatitis / chemically induced
Pancreatitis / genetics*
Pancreatitis / immunology
Pancreatitis / pathology
Proteins / genetics*
Proteins / metabolism
Tissue Array Analysis

Substances

Autoantibodies
Biomarkers, Tumor
Proteins
Ceruletide
CEMIP protein, human
Hyaluronoglucosaminidase

Abstract

Publication types

MeSH terms

Substances

Grants and funding